Literature DB >> 11462020

Human parainfluenza virus type 3 HN-receptor interaction: effect of 4-guanidino-Neu5Ac2en on a neuraminidase-deficient variant.

M Porotto1, O Greengard, N Poltoratskaia, M A Horga, A Moscona.   

Abstract

The envelope of human parainfluenza virus type 3 (HPF3) contains two viral glycoproteins, the hemagglutinin-neuraminidase (HN) and the fusion protein (F). HN, which is responsible for receptor attachment and for promoting F-mediated fusion, also possesses neuraminidase (receptor-destroying) activity. We reported previously that 4-guanidino-neu5Ac2en (4-GU-DANA) and related sialic acid-based inhibitors of HPF3 neuraminidase activity also inhibit HN-mediated receptor binding and fusion processes not involving neuraminidase activity. We have now examined this mechanism, as well as neuraminidase's role in the viral life cycle, using a neuraminidase-deficient HPF3 variant (C28a) and stable cell lines expressing C28a or wild-type (wt) HN. C28a, which has a wt F sequence and two point mutations in the HN gene corresponding to two amino acid changes in the HN protein, is the first HPF3 variant with insignificant neuraminidase activity. Cells expressing C28a HN did not bind erythrocytes at 4 degrees C unless pretreated with neuraminidase, but no such pretreatment was required for hemadsorption activity (HAD) at 22 or 37 degrees C. HAD was blocked by 4-GU-DANA, attesting to the ability of this compound to inhibit HN's receptor-binding activity. C28a or wt plaque enlargement, a process that involves cell-cell fusion and does not depend on virion release, is diminished by the presence of 4-GU-DANA, confirming the inhibitory effect of 4-GU-DANA on the fusogenic function of C28a HN. In C28a-infected cell monolayers, virion release and thus multicycle replication are severely restricted. This defect was corrected by supplementation of exogenous neuraminidase and also by the addition of 4-GU-DANA; neuraminidase destroys the receptors whereby newly formed C28a virions would remain attached to the cell surface, whereas 4-GU-DANA prevents the attachment itself, obviating the need for receptor cleavage. In accord with the ability of 4-GU-DANA to prevent attachment, the neuraminidase inhibitory effect of 4-GU-DANA on wt HPF3 did not diminish virion release into the medium. Thus, it is by inhibition of viral entry and syncytium formation that sialic acid analogs like 4-GU-DANA may counteract wt HPF3 infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11462020      PMCID: PMC114983          DOI: 10.1128/JVI.75.16.7481-7488.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Amino acid substitutions in a conserved region in the stalk of the Newcastle disease virus HN glycoprotein spike impair its neuraminidase activity in the globular domain.

Authors:  Z Wang; R M Iorio
Journal:  J Gen Virol       Date:  1999-03       Impact factor: 3.891

2.  Expression of influenza B virus hemagglutinin containing multibasic residue cleavage sites.

Authors:  D L Brassard; R A Lamb
Journal:  Virology       Date:  1997-09-29       Impact factor: 3.616

3.  Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrate moiety.

Authors:  M Ohuchi; R Ohuchi; A Feldmann; H D Klenk
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Authors:  F G Hayden; A D Osterhaus; J J Treanor; D M Fleming; F Y Aoki; K G Nicholson; A M Bohnen; H M Hirst; O Keene; K Wightman
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

5.  Analysis of human parainfluenza virus 3 receptor binding variants: evidence for the use of a specific sialic acid-containing receptor.

Authors:  A Moscona; R W Peluso
Journal:  Microb Pathog       Date:  1996-03       Impact factor: 3.738

6.  Hemagglutinin specificity and neuraminidase coding capacity of neuraminidase-deficient influenza viruses.

Authors:  P Yang; A Bansal; C Liu; G M Air
Journal:  Virology       Date:  1997-03-03       Impact factor: 3.616

7.  The role of individual oligosaccharide chains in the activities of the HN glycoprotein of Newcastle disease virus.

Authors:  L W McGinnes; T G Morrison
Journal:  Virology       Date:  1995-10-01       Impact factor: 3.616

8.  Neuraminidase is essential for fowl plague virus hemagglutinin to show hemagglutinating activity.

Authors:  M Ohuchi; A Feldmann; R Ohuchi; H D Klenk
Journal:  Virology       Date:  1995-09-10       Impact factor: 3.616

9.  Transfer of an esterase-resistant receptor analog to the surface of influenza C virions results in reduced infectivity due to aggregate formation.

Authors:  K Höfling; R Brossmer; H Klenk; G Herrler
Journal:  Virology       Date:  1996-04-01       Impact factor: 3.616

10.  Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.

Authors:  J L McKimm-Breschkin; A Sahasrabudhe; T J Blick; M McDonald; P M Colman; G J Hart; R C Bethell; J N Varghese
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

View more
  35 in total

1.  Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein.

Authors:  Tatiana Bousse; Toru Takimoto
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site.

Authors:  Matteo Porotto; Micaela Fornabaio; Olga Greengard; Matthew T Murrell; Glen E Kellogg; Anne Moscona
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism.

Authors:  Matteo Porotto; Micaela Fornabaio; Glen E Kellogg; Anne Moscona
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Kinetic dependence of paramyxovirus entry inhibition.

Authors:  Matteo Porotto; Christine C Yokoyama; Gianmarco Orefice; Han-Sung Kim; Mohamed Aljofan; Bruce A Mungall; Anne Moscona
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

5.  Effects of hemagglutinin-neuraminidase protein mutations on cell-cell fusion mediated by human parainfluenza type 2 virus.

Authors:  Masato Tsurudome; Machiko Nishio; Morihiro Ito; Shunsuke Tanahashi; Mitsuo Kawano; Hiroshi Komada; Yasuhiko Ito
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

6.  Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Authors:  Makiko Watanabe; Vasiliy P Mishin; Scott A Brown; Charles J Russell; Kelli Boyd; Y Sudhakara Babu; Garry Taylor; Xiaoping Xiong; Xiaowei Yan; Allen Portner; Irina V Alymova
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

7.  Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery.

Authors:  Shohreh F Farzan; Laura M Palermo; Christine C Yokoyama; Gianmarco Orefice; Micaela Fornabaio; Aurijit Sarkar; Glen E Kellogg; Olga Greengard; Matteo Porotto; Anne Moscona
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

8.  Regulation of paramyxovirus fusion activation: the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state.

Authors:  Matteo Porotto; Zuhair W Salah; Long Gui; Ilaria DeVito; Eric M Jurgens; Hong Lu; Christine C Yokoyama; Laura M Palermo; Kelly K Lee; Anne Moscona
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

9.  Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells.

Authors:  Santanu Bose; Mausumi Basu; Amiya K Banerjee
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry.

Authors:  Matteo Porotto; Barry Rockx; Christine C Yokoyama; Aparna Talekar; Ilaria Devito; Laura M Palermo; Jie Liu; Riccardo Cortese; Min Lu; Heinz Feldmann; Antonello Pessi; Anne Moscona
Journal:  PLoS Pathog       Date:  2010-10-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.